Pharma business news, market intelligence, and CEO-level case studies
Archive
Moderna Flu Vaccine: From FDA Refusal to Two 9-0 Votes | Witfire Elite View Witfire Elite FDA & Regulatory Case Studies Strategy Long Read Pharma Market Case Studies…
GSK Did Not Simply Buy Nuvalent. It Bought Two FDA Decision Dates | Witfire Elite View Witfire Elite Oncology M&A Case Studies Strategy Long Read Pharma Market Case…
FDA Rejects Replimune’s RP1 Despite 34% Response Rate in Melanoma | Witfire Elite View Witfire Elite FDA & Regulatory Case Studies Strategy Long Read FDA & Regulatory Intelligence…
India CRO Boom: Why Chinese Molecules May Build the Next Outsourcing Wave | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case…
Iran War Pharma Shock: India API Dependence vs China Biotech Chokepoints | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Studies…
Novo Nordisk did not lose momentum because CagriSema is a weak drug. That is too simple. The sharper problem is that CagriSema is being asked to solve a…
Witfire Elite View · Pharma Market Case Study · Updated 12 June 2026 The cheapest semaglutide in the world is made in India — and the price collapse…
Eli Lilly Retatrutide Phase 3: 28.3% Weight Loss Pushes Obesity Into a Portfolio War | Witfire Elite View Witfire Elite Pharma News Investments Stock Market Breaking Analysis 28.3…
FTX-6058 and Pociredir: FDA’s PRC2 Risk View Hit a Promising Sickle Cell Drug | Witfire Elite View Witfire Elite FDA & Regulatory Case Studies Strategy Breaking Case Study…
IQVIA Wegovy Pill Data and Oral GLP-1 Market Expansion | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Studies Witfire Elite…